FDA Warns About CCSVI Treatment
The FDA today issued a press release and safety communication about serious risks associated with an experimental procedure used to treat chronic cerebrospinal venous insufficiency (CCSVI). The treatment aims to widen narrowed veins in the chest and neck. The alert includes separate recommendations for people with MS, their physicians and care providers, and clinical investigators and institutional review boards.
DOI:
doi/10.7493/msdf.10.1707.1